Arrowhead Pharmaceuticals (ARWR) Competitors

Blueprint Medicines (NASDAQ:BPMC) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Do insiders & institutionals believe in BPMC or ARWR?

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is BPMC or ARWR more profitable?

Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Blueprint Medicines' net margin of -27.70%. Arrowhead Pharmaceuticals' return on equity of -45.33% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-27.70%	-64.60%	-17.22%
Arrowhead Pharmaceuticals	N/A	-45.33%	-12.49%

Which has more risk and volatility, BPMC or ARWR?

Blueprint Medicines has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Does the media favor BPMC or ARWR?

In the previous week, Blueprint Medicines had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 5 mentions for Blueprint Medicines and 3 mentions for Arrowhead Pharmaceuticals. Blueprint Medicines' average media sentiment score of 0.65 beat Arrowhead Pharmaceuticals' score of 0.59 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Blueprint Medicines	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, BPMC or ARWR?

Blueprint Medicines has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$508.82M	16.30	-$67.09M	-$2.47	-51.98
Arrowhead Pharmaceuticals	$545.21M	4.27	-$599.49M	-$1.40	-12.03

Do analysts rate BPMC or ARWR?

Blueprint Medicines presently has a consensus target price of $128.25, suggesting a potential downside of 0.12%. Arrowhead Pharmaceuticals has a consensus target price of $43.71, suggesting a potential upside of 159.59%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	0 Sell rating(s)	17 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.24
Arrowhead Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Arrowhead Pharmaceuticals beats Blueprint Medicines on 12 of the 17 factors compared between the two stocks.